Literature DB >> 29468378

Achalasia Patients Are at Nutritional Risk Regardless of Presenting Weight Category.

Carolyn Newberry1, Ravy K Vajravelu2, Octavia Pickett-Blakely2, Gary Falk2, Yu Xiao Yang2,3, Kristle L Lynch2.   

Abstract

BACKGROUND: Achalasia is an esophageal motor disorder that leads to swallowing dysfunction and weight loss. Nutritional risk in achalasia patients is not well defined. AIMS: The aims of this study were to define baseline body mass index (BMI), changes in weight, and nutritional risk over time in a large cohort of achalasia patients.
METHODS: This was a retrospective cohort study of achalasia patients at a tertiary care center with documented BMI, symptom severity as per Eckardt score, and nutritional risk assessment as per the Malnutrition Universal Screening Tool, which considers BMI, degree of recent weight loss, and acuity of disease.
RESULTS: Among the 337 patients presenting for achalasia management, 179 had confirmed disease. Upon presentation 69.8% of patients were classified as overweight or obese. Using the Malnutrition Universal Screening Tool, we found 50% of patients to be at moderate or high risk for malnutrition at presentation. Eckardt score (OR 1.15, 95% CI 1.05-1.26), duration of disease (OR for each additional month 1.04, 95% CI 1.01-1.08), and female gender (OR 1.76, 95% CI 1.02-3.03) were independent predictors of increased risk for malnutrition. Nutrition risk score decreased after therapy in 93.3% of patients.
CONCLUSIONS: Despite a high prevalence of overweight and obese status in achalasia patients, many are at risk of developing nutritional complications secondary to rapid weight loss. This risk frequently resolves post-treatment. Regardless of baseline BMI, we recommend all patients undergo nutritional assessment to identify high-risk patients who may benefit from dietary intervention and expedited therapy.

Entities:  

Keywords:  Achalasia; Dysphagia; Malnutrition; Obesity; Weight loss

Mesh:

Year:  2018        PMID: 29468378     DOI: 10.1007/s10620-018-4985-8

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  13 in total

1.  Obesity: preventing and managing the global epidemic. Report of a WHO consultation.

Authors: 
Journal:  World Health Organ Tech Rep Ser       Date:  2000

2.  National outcomes of laparoscopic Heller myotomy: operative complications and risk factors for adverse events.

Authors:  Samuel W Ross; Bindhu Oommen; Blair A Wormer; Amanda L Walters; Brent D Matthews; B T Heniford; Vedra A Augenstein
Journal:  Surg Endosc       Date:  2015-01-15       Impact factor: 4.584

Review 3.  Chicago classification criteria of esophageal motility disorders defined in high resolution esophageal pressure topography.

Authors:  A J Bredenoord; M Fox; P J Kahrilas; J E Pandolfino; W Schwizer; A J P M Smout
Journal:  Neurogastroenterol Motil       Date:  2012-03       Impact factor: 3.598

4.  BMI affects presenting symptoms of achalasia and outcome after Heller myotomy.

Authors:  S S Rakita; D Villadolid; C Kalipersad; D Thometz; A Rosemurgy
Journal:  Surg Endosc       Date:  2006-12-04       Impact factor: 4.584

5.  The Chicago Classification of esophageal motility disorders, v3.0.

Authors:  P J Kahrilas; A J Bredenoord; M Fox; C P Gyawali; S Roman; A J P M Smout; J E Pandolfino
Journal:  Neurogastroenterol Motil       Date:  2014-12-03       Impact factor: 3.598

Review 6.  Treatment and surveillance strategies in achalasia: an update.

Authors:  Alexander J Eckardt; Volker F Eckardt
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2011-04-26       Impact factor: 46.802

7.  Long-term outcome of pneumatic dilation in the treatment of achalasia.

Authors:  Michael Hulselmans; Tim Vanuytsel; Toon Degreef; Daniel Sifrim; Willy Coosemans; Toni Lerut; Jan Tack
Journal:  Clin Gastroenterol Hepatol       Date:  2009-09-25       Impact factor: 11.382

Review 8.  Update on therapeutic interventions for the management of achalasia.

Authors:  Nishmi Gunasingam; Adam Perczuk; Michael Talbot; Arthur Kaffes; Payal Saxena
Journal:  J Gastroenterol Hepatol       Date:  2016-08       Impact factor: 4.029

9.  Clinical, radiological, and manometric profile in 145 patients with untreated achalasia.

Authors:  Piero M Fisichella; Dan Raz; Francesco Palazzo; Ian Niponmick; Marco G Patti
Journal:  World J Surg       Date:  2008-09       Impact factor: 3.352

10.  Clinical Characteristics of Patients with Untreated Achalasia.

Authors:  Han Ho Jeon; Jie-Hyun Kim; Young Hoon Youn; Hyojin Park; Jeffrey L Conklin
Journal:  J Neurogastroenterol Motil       Date:  2017-07-30       Impact factor: 4.924

View more
  5 in total

Review 1.  Achalasia.

Authors:  Edoardo Savarino; Shobna Bhatia; Sabine Roman; Daniel Sifrim; Jan Tack; Sarah K Thompson; C Prakash Gyawali
Journal:  Nat Rev Dis Primers       Date:  2022-05-05       Impact factor: 52.329

2.  Evaluating the impact of an enhanced triage process on the performance and diagnostic yield of oesophageal physiology studies post COVID-19.

Authors:  Rebecca Doyle; Sebastian Bate; Jade Devenney; Sophia Agwaonye; Margaret Hastings; Jane Wych; Sharon Archbold; Dipesh H Vasant
Journal:  BMJ Open Gastroenterol       Date:  2021-12

3.  Esophageal Microbiota and Nutritional Intakes in Patients With Achalasia Before and After Peroral Endoscopic Myotomy.

Authors:  Da Hyun Jung; Young Hoon Youn; Do Hoon Kim; Chul-Hyun Lim; Hee-Sook Lim; Hee Seok Moon; Ju Yup Lee; Hyojin Park; Su Jin Hong
Journal:  J Neurogastroenterol Motil       Date:  2022-04-30       Impact factor: 4.924

4.  Perception of the COVID-19 pandemic in patients with achalasia and its impact on gastrointestinal symptoms: a proof-of-concept study.

Authors:  Luigi Ruggiero; Paola Iovino; Chiara Ameno; Rossella Palma; Antonella Santonicola
Journal:  Ann Gastroenterol       Date:  2022-07-30

5.  Rehospitalization, Treatment, and Resource Use After Inpatient Admission for Achalasia in the USA.

Authors:  Kamesh Gupta; Ahmad Khan; Jean Chalhoub; Kevin Groudan; David Desilets
Journal:  Dig Dis Sci       Date:  2021-01-01       Impact factor: 3.199

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.